Content Hub

An Exclusive Interview With

Hellen Kuasne
Research Associate
McGill University

Developing novel treatments for TNBC that overcome the bar set by the standard of care is difficult, as demonstrated by the recent news of Roche’s ipatasertib program. Despite this, the TNBC patient population continues to present as a difficult to treat tumor with a significant remaining unmet need and very low five-year survival rates, that continues to drive therapeutic innovation...

TNBC Summit - Content Piece